BURLINGAME, CA, UNITED STATES, June 26, 2025 /EINPresswire.com/ -- Fast Melt Tablets Market is estimated to be valued at US$ 6.20 Bn in 2025 and is expected to reach US$ 11.41 Bn ...

GSK confirmed the transaction and Cleary's role on the London Stock Exchange on Wednesday, as it said it would pay $1.2 billion upfront for efimosfermin—a liver disease drug in late-stage trials.

Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q3 Results for 2024.

In Brazil, a retrospective study of 96 HIV positive individuals treated with ABC and 234 HIV negative individuals from Pernambuco State, at Northeast region, has found allele frequencies of 1.5 and ...

GSK expects to extend beyond that three years, Miels said. The market for Shingrix in China, and also in Brazil and Mexico is “largely out-of-pocket”, and the vaccine’s launch in those ...

GSK is aiming to move the 30-plus candidate into the clinic in 2025. Pfizer has (PDF) a 25-valent vaccine candidate in phase 2 and a 30-plus valent program in preclinical.

MARIETTA, Pa. — Hundreds of millions of dollars and hundreds of new jobs are coming to Lancaster County. Vaccine manufacturer GSK announced Thursday it will invest $800 million to expand its ...

GSK recently announced the discontinuation of its herpes simplex virus (HSV) therapeutic vaccine candidate, GSK3943104, following the failure of a Phase I/II clinical trial to meet its primary ...

In Brazil, the urgency of the public health emergency in the Yanomami Special Indigenous Health District, where P. vivax malaria is particularly prevalent, led to the accelerated approval of ...

GSK plans to launch an every-four-month version of Apretude in 2026 and start a registrational study for a twice-yearly option in 2027, the company said during an investor update in September.

China's largest vaccines company Zhifei will pay British drugmaker GSK 2.5 billion pounds ($3.05 billion) for the exclusive rights to distribute GSK's shingles vaccine in the world's No.2 ...